28
Participants
Start Date
August 31, 2012
Primary Completion Date
November 30, 2018
Study Completion Date
November 30, 2018
Inhaled Lipid Cisplatin (ILC)
ILC is provided as cisplatin in a lipid complex suspended in a saline solution. Every two weeks, the patient will receive 36 mg/m2 (measured as concentration of cisplatin) of ILC via nebulization. Treatment may continue for up to 1 year.
Memorial Sloan-Kettering Cancer Center, New York
The Children's Hospital at Montefiore, The Bronx
H. Lee Moffitt Cancer Center, Tampa
Vanderbilt-Ingram Cancer Center, Nashville
Mayo Clinic, Rochester
University of Chicago, Chicago
Washington University School of Medicine, St Louis
Ochsner Clinic Foundation, New Orleans
UT Southwestern Medical Center, Dallas
Baylor College of Medicine/Texas Children's Hospital, Houston
Primary Children's Medical Center, Salt Lake City
Children's Hospital Los Angeles, Los Angeles
Stanford University Medical Center, Palo Alto
Seattle Children's Hospital, Seattle
Dana-Farber Cancer Institute, Boston
Lead Sponsor
Eleison Pharmaceuticals LLC.
INDUSTRY